Feb 4, 2009 - Pfizer Inc said today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document recommending the use of Sutent (sunitinib malate) as a first-line treatment for patients with metastatic renal cell carcinoma mRCC (advanced kidney cancer).
The details can be read here.
No comments:
Post a Comment